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Abstract
Background: Excessive subcutaneous adiposity in obesity is associated to positive white adipocyte tissue (WAT)
differentiation (adipogenesis) and WAT expandability. Here, we hypothesized that supplementation with the insulin
inhibitor and mitochondrial uncoupler, Tyrphostin (T-AG17), in vitro and in vivo inhibits adipogenesis and adipocyte
hypertrophy.
Methods: We used a 3T3-L1 proadipocyte cell line to identify the potential effect of T-AG17 on adipocyte
differentiation and fat accumulation in vitro. We evaluated the safety of T-AG17 and its effects on physiological and
molecular metabolic parameters including hormonal profile, glucose levels, adipogenesis and adipocyte
hypertrophy in a diet-induced obesity model using C57BL/6 mice.
Results: We found that T-AG17 is effective in preventing adipogenesis and lipid synthesis in the 3T3-L1 cell line, as
evidenced by a significant decrease in oil red staining (p < 0.05). In obese C57BL/6 mice, oral administration of
T-AG17 (0.175 mg/kg for 2 weeks) lead to decreased fat accumulation and WAT hypertrophy. Further, T-AG17
induced adipocyte apoptosis by activating caspase-3. In the hepatocytes of obese mice, T-AG17 promoted an
increase in the size of lipid inclusions, which was accompanied by glycogen accumulation. T-AG17 did not alter
serum biochemistry, including glucose, insulin, leptin, free fatty acids, creatinine, and aspartate aminotransferase.
Conclusion: T-AG17 promotes adipocyte apoptosis in vivo and is an effective modulator of adipocyte
differentiation and WAT hypertrophy in vitro and in vivo. Therefore, T-AG17 may be useful as a pharmacological
obesity treatment.
Keywords: Tyrphostin, AG17, Adipogenesis, Obesity, Hepatic steatosis, Oxidative phosphorylation, Thermogenesis,
Mitochondrial uncoupling, Adipocyte differentiation
Background
Excessive subcutaneous adiposity and its accumulation
into visceral depot during obesity are major risk factors
for developing type 2 diabetes (T2DM) and several other
chronic metabolic disorders [1, 2]. Therefore, identifying
therapeutic targets to treat the metabolic failures associated
with obesity could reduce or prevent the development of
these incurable metabolic disorders. Two cellular signaling
pathways that may contain potential drug targets are the
white adipose tissue (WAT) differentiation pathway, also
referred to as adipogenesis, and the WAT expandability
pathway.
During early development, mesenchymal stem cells
differentiate into chondrocytes, osteoblasts, myoblasts
and adipocytes [3]. Adipocyte differentiation from mes-
enchymal stem cells is modulated by signaling cascades
involving bone morphogenetic protein-4 and peroxi-
some proliferator-activated receptor (PPAR) β/δ, which
support the gene expression of PPARγ [4]. In adults,
ectopic accumulation of adipocytes might be caused by
dysfunction in differentiation pathways, which creates
* Correspondence: acm590@hotmail.com; alberto.camachomr@uanl.edu.mx;
rortizlopez@gmail.com
1Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina,
Universidad Autónoma de Nuevo León (UANL), Monterrey, Mexico
5Unidad de Genómica, UANL, CIDICS, Monterrey, Mexico
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Camacho et al. Lipids in Health and Disease  (2018) 17:128 
https://doi.org/10.1186/s12944-018-0784-7
an inability to induce differentiation of adipocyte pre-
cursor cells [3, 5] or induce adipocyte de-differentiation
[6]. On the other hand, once obesity is reached, the
number of new adipocytes decreases, and adipocytes
become hypertrophic, reaching their expandability limit
until fat accumulates around ectopic organs, resulting
in metabolic complications [7, 8].
Drugs that act on mitochondria have been used to
combat fat accumulation by forcing cells to use stored
energy. Mitochondrial oxphos uncouplers create a futile
cycle of glyceride and fatty acid oxidation without gener-
ating adenosine triphosphate (ATP). 2,4-dinitrophenol
(DNP) is one of the best known uncoupler of oxphos
widely used as a weight loss agent between 1933 and
1938; however, DNP has been banned due to its high
acute toxicity [9]. Further studies on DNP and other re-
lated prodrugs consistently show that the toxic effects
are dose-dependent. Mild mitochondrial uncoupling
(MMU) with low doses, which seem effective at thermo-
neutrality (30 °C) conditions, may provide a promising
strategy to reduce body weight with general tolerability
[10–18]. Side effects of DNP exposure might be pre-
vented, and MMU might also promote longevity through
decreased ROS levels, mitochondrial biogenesis, down-
regulation of the mTOR and insulin signaling pathways,
and upregulation of autophagy [12, 13]. Of interest,
these effects are similar to those seen in caloric restric-
tion [12, 15, 19] and are consistent with the “uncoupling
to survive” hypothesis [20]. These potentially beneficial
effects of MMU may also be induced by niclosamide
ethanolamine [21], salsalate [22], TTFB [23], CZ5 [24],
FCCP [6, 17, 25–27], the niclosamide-ethanolamine
aduct [21] and certain tyrphostins [28].
Tyrphostins belong to the benzylidenemalononitrile
family, which possess a benzene ring pharmacophore, an
exocyclic carbon-carbon double bond, and a cyano group
(CN) located at the same side of the molecule (cis) as the
aromatic ring [29, 30]. The tyrphostin T-AG17 is a
highly selective, reversible inhibitor of epidermal
growth factor receptor-induced phosphorylation of
tyrosine residues of intracellular proteins [31], and
its cellular effect is dose-dependent growth inhibition.
T-AG17 has potential therapeutic value for treating
neurodegenerative disorders [28], atherosclerosis [32], dys-
lipidemia [33], restenosis [34], and cancer/cell hyperproli-
feration [35], partially due to the reduction of free radical
production in mitochondria [28, 36], activation of Nrf2
transcription factor [37], reduction of CDK2 kinase activity,
as well as causing reduced p21 and p16 protein levels [38]
and decreased in STAT3 phosphorylation [39]. Notably,
T-AG17 suppresses insulin-mediated fatty acid synthesis in
WAT of rats [33], and tyrphostins B46 and A47 (which
bear the same pharmacophore as T-AG17) block GLUT1-
mediated intracellular glucose transport [40]. Importantly,
T-AG17 is also a potent inhibitor of mitochondrial oxphos
and is capable of increasing energy expenditure. How-
ever, the effects of T-AG17 on adipocyte differentiation,
adipose tissue hypertrophy and body organ toxicity
have not been evaluated.
Considering the significant suppressive effects of T-AG17
on insulin signaling, we hypothesized that T-AG17 might
promote inhibition of adipogenesis and/or adipocyte hyper-
trophy. Specifically, we seek to determine if T-AG17: 1)
decreases lipid accumulation in the 3T3-L1 adipocyte cell
line induced by insulin and 2) promotes adipocyte apop-
tosis in a diet-induced obesity mouse model.
Methods
Reagents and antibodies
3T3-L1 preadipocyte cell line (Cat. CL-173) and newborn
calf serum (Cat. 30-2030) were purchased from ATCC,
Inc. Dulbecco’s Modified Eagle’s Medium-high glucose
(Caisson Labs, Cat.), Penicillin-Streptomycin (Cat.
P4333), Fetal Bovine Serum (Gibco), Oil Red O (Cat.
O0625), Dimethyl sulfoxide (Cat. D2650), isopropyl
alcohol (Cat. W292907), Formalin solution neutral
buffered 10% (Cat. HT501128), Ethyl alcohol (Cat.
E7023), Harris hematoxylin (Cat. HHS16), Sodium
citrate (Cat. 1613859), Triton X-100 (Cat. X100), Corn-
ing® cell culture flasks surface area 75 cm2, canted neck,
cap (vented) (CLS430641) were from SIGMA-ALDRICH.
Paraplast® Embedding Media, (Cat. 15159-409, McCormick
Scientific), Rabbit polyclonal to Active + pro Caspase 3
(Cat. AB13847, ABCAM), Goat polyclonal secondary anti-
body to Rabbit IgG H&L (alexa Fluor® 488) preadsorbed
(Cat. AB150081, ABCAM), and VECTASHIELD Hardset
antifade mounting medium with DAPI (cat no. H-1500
Vector laboratories).
Adipogenesis Assay Kit for 3T3-L1 preadypocyte differ-
entiation was purchased from Abcam (Cat. Ab133102).
Also, the primary antibody cleaved Caspase-3 (Asp175)
(Cat. 9661. Cell signaling) and secondary antibody
Anti-rabbit IgG (H + L), Alexa Fluor® 488 Conjugate (Cat.
4412. Cell signaling) were used. ELISA kits: creatinine
(SIGMA. MAK080), aspartate aminotransferase (SIGMA.
MAK055), free fatty acids (Roche, 11383175001), insulin
(Millipore, Cat. EZRMI-13 k) and leptin (Millipore, Cat.
EZML-82 K). Acucheck (Cat. 05987270) and glucose
strips (6454011023, Roche). 10% Phosphate-buffered
saline (PBS) Formalin solution (Cat. SF100–20, Fischer
Scientific), Isopropyl alcohol (Cat. 9084-03 J.T. Baker),
Ethyl alcohol (Cat. E7023), Trichloromethane (Cat.
616778, Sigma Aldrich), Acetic acid, glacial (Cat.193829
MP Biomedicals, Inc.), Histological grade xylene (Cat.
534056 Sigma Aldrich), Paraplast® Embedding Media, (Cat.
15159-409, McCormick Scientific), Eosin–Y 7111 (Richar-
d-Allan Scientific), Hematoxylin 7212; (Richard-Allan
Scientific), Tissue tek O.C.T. (Cat.4530 Sakura), Oil red
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(Cat.00625-25g Sigma Aldrich), Schiff ’s reagent (Cat.
3952016 Sigma Aldrich), 99% Periodic Acid (Cat. P7875,
Sigma Aldrich).
T-AG17stock solution
The T-AG17 was provided by Ayon Industries (Monterrey,
México). T-AG17 was synthesized by reacting (under re-
flux) 4-hydroxy-3,5-di-tert-butylbenzaldehyde (99.1% pure,
purchased from Yongyi Chemicals Group Co., Ltd.,
Changzhou, Jiangsu, China) with malononitrile in an-
hydrous ethanol solvent, using ammonium acetate as cata-
lyst. This procedure gives a 95% yield of a light-yellow
microcrystalline solid that melts at 141–142 °C, presents
UV absorption maxima at 247 and 365 nm and has an Rf
value of 0.65 (using benzene as eluent and Merck’s TLC
silica gel 60 F254 plastic-backed sheets), with only one spot
being observed.
The mixed melting point of this compound and
authentic T-AG17 (acquired from Cayman Chemical)
was 141–142 °C, and its spectroscopic and chromato-
graphic properties were identical to those of the authen-
tic product. This compound is stable, with a shelf life of
over 2 years at 25–35 °C. If necessary it may be recrys-
tallized from ethanol.
Stock solutions were prepared in Dimethyl sulfoxide
(DMSO; Sigma-Aldrich, D2650). DMSO was used as the
vehicle control.
3T3-L1 cell line maintenance and treatments
The 3T3-L1 preadipocyte cell line was expanded in Corn-
ing® T75 cm2 flasks with Dulbecco’s modified Eagle’s
medium (DMEM, high glucose 4.5 g/l; (Caisson Labs),
supplemented with 10% (vol/vol) newborn calf serum,
50 units/ml penicillin, and 50 μg/ml streptomycin in 5%
CO2 incubator at 37 °C. After confluence, cells were in-
duced to adipocyte differentiation for 7 days by using
DMEM supplemented with 10% vol/vol fetal bovine
serum, 1 μM dexamethasone, 0.5 mM isobutylmethyl-
xanthine, 100 nM insulin, and 50 units/ml penicillin and
50 μg/ml streptomycin. The T-AG17 (1 μM) or equivalent
concentration of DMSO (vehicle control) was added be-
fore (day 0) or after (day 7) adipogenic induction.
Quantification of lipid accumulation in cells
Effect of T-AG17 on the accumulation of cellular lipid
droplets was conducted by comparing T-AG17-treated
cells to vehicle control-treated cells after 7 days by using
the oil red solution to stain the cells following manufac-
turer’s instructions. Digital images of the cells were
taken with a PrimoVert microscope and the AxioCam
ERc5s camera (Zeiss). The stain was extracted from the
cells using 60% isopropyl alcohol for 1 h (10 ml/flask),
and the extract (1 ml) was measured at 510 nm in the
iMark Microplate Absorbance Reader (Bio-Rad).
Animals and housing
All the experiments were performed using 2 month-old
male C57BL/6 mice. Animals were handled according to
the NIH guide for the care and use of laboratory animals
(NIH Publications No. 80–23, revised in 1996), and
animal protocols were approved by the Local Animal
Care Committee. All the animals were housed individu-
ally in Plexiglas cages and maintained at 20–23 °C in a
temperature-controlled room with a 12-h light/dark
cycle. Water and food was available ad libitum in the
home cage.
Mice long-term feeding and treatments
Animals were housed a week before the experiment as
described above. Mice were exposed to either a high-fat
diet (HFD, 45% kcal from fat; Research Diets, D12451)
or a basic Chow diet (CHOW, 10% kcal from fat;
Research Diets, D12450B) for 13 weeks, as described in
our previous studies [41, 42].
T-AG17 or vehicle control were administered orally
(via gavage) or injected intraperitoneally (i.p.), and body
weight, food intake and water consumption were re-
corded every week. Doses of 1.75, 5.5, 17.5, 28, 40 and
55 mg/kg were administered once to determine the
LD50, and doses of 0.175, 0.0175 and 0.00175 mg/kg
were administered daily for 15 days to determine the
therapeutic effects.
Tissue sample collection and histological analysis
Mice were sacrificed by cervical dislocation and blood
samples were collected using syringe cardiac punch
(22G diameter). Serum was isolated as described below.
Brain, liver, adipose tissue, pancreas, spleen, gonadal
tissue and skeletal muscle were collected and fixed as
described below and stained for: hematoxylin/Eosin (H/E;
Richard-Allan Scientific), oil red, periodic acid–Schiff
(PAS) and active pro-caspase 3 immunofluorescence.
Serum biochemistry
Blood samples were collected in a Microtainer and cen-
trifuged at 5000 rpm × 10 min. We determined serum
biochemical composition including glucose levels by
glucose strips and insulin, creatinine, aspartate amino-
transferase, leptin and free fatty acids were determined
by Elisa kits according to manufacturers’ instructions:
creatinine, aspartate aminotransferase, free fatty acids,
insulin and leptin.
Hematoxylin and Eosin staining (H&E)
Samples were fixed in 10% formaldehyde in PBS during
24 h, following by automating processing in an auto-
mated (Excelsior ES system®, Thermo Scientific. Inc.).
Samples were included in paraffin and 4-μm slices were
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obtained using a microtome (Microm HM355S. Thermo
Scientific. Inc.). Finally, samples were stained with H&E.
Oil red staining for lipid accumulation in tissue samples
In brief, samples were fixed in 10% formaldehyde in PBS
during 24 h, included in “tissue tek” (Tissue-Tek® OCT
Compound, TEC Pella, Inc) and 9-μm sections were ob-
tained using a cryostat (Microm HM 550®, Thermo
Scientific.Inc). Slides were stained in oil red and counter-
stained with Harris hematoxylin.
PAS (Periodic Acid Schiff) staining
Samples were fixed in Carnoy’s solution by 2 h, dehy-
drated with isopropyl alcohol overnight, pre-included in
paraffin and cut 4-μm sections were obtained.
For PAS staining samples were reduced in 0.5% peri-
odic acid solution, placed in Schiff reagent and counter-
stained in Harris hematoxylin.
Staining protocols were implemented systematically
using the automated staining equipment, Varistain Gemini
ES® (Thermo Scientific Inc.).
Immunofluorescence staining
Paraffin slides previously fixed in Carnoy’s solution by
2 h, were processed for antigen retrieval system using
10 mM sodium citrate buffer, pH 6.0 using an auto-
mated computing assisted Lab Vision™ PT Module
(Thermo Fisher Scientific) and blocking of unspecific an-
tigens was performed using 5% normal goat serum in
0.2% Triton X-100 (Sigma-Aldrich, X100) in PBS 1 mM,
pH 7.4, for 1 h. Sections were incubated with active
pro-caspase 3 primary antibody (1:2500) for 4 h at room
temperature and incubated with Alexa Fluor® 488 Conju-
gate and anti-rabbit secondary antibody (1:500) for 1 h
at room temperature in the darkness. Entire protocol was
run into automated immunochemistry computing assisted
equipment, Lab Vision™ Autostainer 360® (Thermo
Fisher Scientific). Sections were mounted in cover slip
using synthetic mounting medium with DAPI (Vector
Laboratories, H-1500).
Light microscopy
Histological slides were observed in a bright field
microscope (AxioImager Z1®, Zeiss, Inc.) using a 40×
objective. Five fields from each slide, using axio vision
software (ver. 4.8.2) were acquired. Morphological ana-
lysis of slides from visceral fat tissue were performed by
stained with Hematoxylin and eosin stain (H&E), in-
cluded form of adipocytes. Slides stained with PAS were
used to search cytoplasmic inclusions reacting with
PAS. Morphological analysis of slides from liver stained
with H&E included structure of hepatic lobules, the as-
pect of cytoplasm from hepatocytes, also the form and
aspect of nucleus and it’s chromatin. Presence of oil
drops were searched in slides stained with red oil and
presence of cytoplasmic inclusions of glycogen in slides
stained with PAS.
Confocal microscopy
Active pro-caspase 3-Cy3 stainning in liver and adipose
tissue sections were analyzed by confocal microscopy
(Axio imager Z1®. Zeiss, Inc.), using an EC Plan-Neofluar
(Plan-Neofluar) 40×/1.30 Oil DIC M27; and 488 nm laser.
We scanned for immunoreactive cells using 491/551 nm
(Exc/Emi) (LSM 710 scanner, Zeiss, Inc) and ZEN soft-
ware (Zeiss 2009) for acquisition of 8-bit images collected
over a 45,000 μm2 surface area.
Statistical analysis
The data presented here was analyzed using the Student
t-test or analysis of variance (ANOVA) with post-hoc
tests using the program StatView Version 4.5 (Abacus
Concepts, Berkeley, California, United States). For im-
munofluorescent semiquantitative analysis, we used the
ANOVA test followed by Kruskal-Wallis one-way test
using Number crunched statistical software (NCSS, LLC,
Utah, United States). The data are presented as mean ±
SEM, unless otherwise stated; p < 0.05 was considered
significant. The significance levels displayed on figures
are as follows: * indicates p < 0.05, ** p < 0.001.
Results
T-AG17 blocks adipocyte differentiation in 3T3-L1 cell line
We tested whether T-AG17 prevents the adipocyte dif-
ferentiation of the 3T3-L1 cell line. After cells were
confluent, adipocyte differentiation was induced for
7 days in the presence of T-AG17 or vehicle control
(DMSO). Adipocyte differentiation was detected by cel-
lular uptake of the oil red stain, which was strikingly in-
duced by treatment with an adipogenic cocktail (insulin
stimulation) (Fig. 1a). In the presence of the adipogenic
cocktail with T-AG17 (1 μM), there was a visible reduc-
tion in the number of positively stained cells and degree
of staining per cell (Fig. 1a).
In order to quantify the amount of oil red that the
cells absorbed, we extracted the stain and read the
absorbance of the extract by a microplate absorbance
reader (Fig. 1b). The adipogenic cocktain caused a sig-
nificant increase in extract absorbance as compared to
the DMEM + 10% FBS control treatment group. No dif-
ferentiation was observed with the DMEM + 10% FBS,
DMEM + T-AG17 and DMEM + 0.5% DMSO control
treatment groups as expected. T-AG17 treatment on day 0
(when the adipogenic cocktail was first added) caused a
significant decrease in absorbance to levels similar to the
DMEM + 10% FBS control levels. We found a modest de-
crease with the vehicle control treatment (adipogenic
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cocktail + 0.05% DMSO). This finding suggested that
T-AG17 prevents adipocyte differentiation.
Acute doses of T-AG17 and determination of LD50
We determined the LD50 and therapeutic dose for T-AG17
using C57BL/6 mice. We found that oral T-AG17 adminis-
tration caused increased mortality at 28, 40 and 55.5 mg/kg
doses, with no effect observed for 1.75, 5.5 and 17.5 mg/kg
doses. The 55 mg/kg dose killed all animals within 15 min
due to cardiac failure. Administration of 28 mg/kg or
40 mg/kg doses caused all animals to die after seven and
2 days, respectively. We found that 40 mg/kg administra-
tion induced a 60% mortality rate, suggesting that the LD50
value for this compound in mice is 33.3 mg/kg. Animals
that survived after 2 weeks post T-AG17 administration
(5.5, 17.5, 28.5, 40 or 55 mg/kg) did not show altered serum
levels of glucose, insulin and leptin (Fig. 2).
When we looked at behavioral alterations, we observed
that the animals administered with 1.75, 5.5 and
17.5 mg/kg exhibited inhibition in locomotion and
piloerection, which lasted up to 30 min after administra-
tion. With 28 mg/kg, mice also exhibited increased heart
rate 5 min after administration and a red appearance of
the footpads. One mouse developed prostration and lung
spasms after receiving 28 mg/kg. This mouse was
sacrificed by cervical dislocation. Thirty minutes after
T-AG17 administration, mice recovered mobility. At
40 mg/kg, mice showed the same physiological parame-
ters as the 28 mg/kg dose, and the mice also exhibited
hyperventilation Three out of five mice were sacrificed by
cervical dislocation due to irreversible negative physio-
logical effects. Two of the mice recovered after 30 min.
Finally, the 55 mg/kg T-AG17 dose showed exacerbation
of the behavioral and physiological parameters exhibited
Fig. 1 T-AG17 inhibits adipocyte differentiation. a 3T3-L1 preadipocyte cells were plated and stimulated with adipogenic cocktail (insulin stimulation).
Preadipocytes were incubated with 1μM T-AG17 during 7 days. 3T3-L1 preadypocite lipid droplet staining showed lipid accumulation in cells treated
with the adipogenic cocktail. Lipid accumulation was not detected in cells treated with 1μM T-AG17. b Adipocyte differentiation was evaluated by
quantifying absorbance at 490 nm. Graphs show mean ± SEM for triplicate experiments and statistical significance after using unpaired Student’s t test.
*p < 0.05. n = 3. In some experiments, T-AG17 was added after preadipocyte differentiation (1 and 2 μM)
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at the 40 mg/kg dose. The mice of this group were sacri-
ficed between 5 and 10 min after administration.
We identify changes in cell morphology of brain, kid-
ney, liver, pancreas, adipose tissue and muscle after 17.5,
28 and 55.5 mg/kg T-AG17 oral administration. The
brain showed hyperchromic cytoplasm, perinuclear eo-
sinophilic inclusions and dispersed chromatin. The
kidneys of these mice showed pale aspects of the glom-
erular units and proximal tubules. The liver displayed
hepatic acinar cells with perinuclear cytoplasmic vacu-
oles and and the acinar unit randomly distributed. The
pancreas displayed exocrine acinar cells with pale ap-
pearance and normal Langerhans islets. White adipose
tissue exhibited adipocytes with normal aspect and an
apparent decrease in adipocyte cell number intercalated
with major adipocytes evidenced by the red oil stained.
The skeletal muscle of these mice seemed morphologic-
ally unaltered.
Mice orally administered 41 mg/kg T-AG17 showed
neurons displaying eosinophilic and pale cytoplasm and
pycnotic nucleus coexisting with normal neurons. Kid-
ney cells seem retracted with pale glomeruli and tubular
cells with poor staining, pycnotic nuclei, and condensed
chromatin. Hepatocytes from the liver displayed pale
cytoplasms and large perinuclear vacuoles. Some areas
had low affinity for staining and others areas had disor-
ganized hepatocytes, edema, and the appearance of fat
accumulation as evidenced by oil red staining.
Chronic doses of T-AG17 administration
In order to test the potential of T-AG17 oral administration
to regulate body weight, we selected the lowest dose
administered in our previous experiment (Fig. 2, oral dose
AG17 = 1.75 mg/kg). Mice were orally dosed with 0.175,
0.0175 or 0.00175 mg/kg T-AG17 during 2 weeks reaching
2.45, 0.245 and 0.0245 mg/kg final concentrations after
treatment (Fig. 3). We determined plasma biochemistry and
tested for renal and liver damage using selective markers.
We found that oral 0.175, 0.0175 or 0.00175 mg/kg T-AG17
doses did not alter plasma biochemistry markers including
glucose, leptin, insulin and free fatty acids and nor the
creatinine and aspartate aminotransferase (two markers of
renal and liver damage, respectively) (Fig. 3).
T-AG17 promotes apoptotic cell death of white
adipocytes in obese mice
Based on the observation that T-AG17 stimulation
promotes apoptotic cell death in 3T3-L1 cell line, we
Fig. 2 Acute T-AG17 administration does not alter body weight, glucose, insulin and leptin serum levels. a Body weight was analyzed every week
after 17.5, 28.5, 40 and 55.5 mg/kg oral T-AG17. Changes in body weight are expressed in grams. b-d Serum biochemistry was determined using
ELISA kits (insulin and leptin) as described in Methods and glucose levels measurement was determined by Glucose strips. Graphs show the
normalized results of mean ± SEM for n = 6
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sought to determine if administration of T-AG17 in
mice modulates thermogenesis or white adipose tissue
apoptosis, leading to body weight decrease. Initially,
we fed mice with Chow or HFD for 18 weeks and
tested the potential of T-AG17 versus dieting. In this
experiment, we injected T-AG17 intraperitoneally
(grey bar Fig. 4c) or exposing the HFD mice to a nor-
mal Chow diet (red bar Fig. 4c) for 2 weeks. As
expected, we found that 18 weeks of HFD intake
increased the body weight reaching 45–50 g when
compared to Chow diet values (25–28 g) (Fig. 4a, b).
No significant changes in food intake were found
(Chow = 23.91 ±2.07 g, HFD = 26.83 ±9.72). HFD in-
take increased the body weight (black bar vs Chow
diet, Fig. 4c); however, we did not find evidence of
weight loss after T-AG17 administration (compare
black bar HFD groups vs grey bar Fig. 4c). The latter
observation correlates which we found when mice
were put back to the Chow diet during 2 weeks
(compare black bar HFD groups vs red bar Fig. 4c).
Next, we assessed any morphological changes in
WATafter T-AG17 or dieting exposure. WAT of mice
fed the Chow diet showed typical polyhedral cells with
nuclear location near the plasma membrane; whereas,
cells of mice exposed to HFD reached a higher apparent
size (Fig. 5). Notably, obese mice administered the
T-AG17 showed an apparent decrease in adipocyte fat
droplet size when compared to Chow and HFD groups
(Fig. 5). Also, T-AG17 administration of mice expose to
Chow diet did not show morphological changes when
compare to Chow and HFD groups. In addition, we did
not identify positive staining using the PAS protocol for
visceral fat tissue in all groups (Fig. 5). T-AG17 induced
a significant increase in active pro-caspase 3-Cy3 stain-
ing in obese mice when compared to controls fed with
Chow diet (Fig. 5). This effect was replicated in obese
mice put back to normal Chow diet for 2 weeks (Fig. 5);
however, positive pro-caspase 3-Cy3 staining of cells was
not significant when compared to obese mice adminis-
tered T-AG17 (Fig. 5).
T-AG17 promotes changes in hepatocytes of obese mice
We then assessed any morphological changes in the
livers after T-AG17 or dieting exposure. The livers of
mice exposed to HFD showed abnormal retention of
lipids displaying macrovesicular steatosis (Fig. 6a). Oral
T-AG17 administration led to a transition from macro-
vesicular to microvesicular steatosis, which correlated
with an increase in red oil positive inclusions (lipids)
(Fig. 6a, b). Obese mice put back on Chow diet for
Fig. 3 Chronic T-AG17 does not alter body weight, glucose, insulin, and leptin levels and creatinine and aspartate aminotransferase activity in
serum. a Body weight was analyzed every week after 2 weeks of 0.0175, 0.175 and 1.75 mg/kg oral T-AG17 administration. Changes in body
weight are expressed in grams. b-e Blood glucose levels were determined using glucose strips and serum biochemistry was determined using
ELISA kits as described in Methods. f-g Creatinine and aspartate aminotransferase activity were determined using ELISA kits. Graphs show the
normalized results of mean ± SEM for n = 6
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2 weeks showed a similar hepatocyte morphology as
the Chow diet group and also showed a switch from
macrovesicular to microvesicular steatosis. Notably, oral
T-AG17 administration promoted a significant increase in
caspase-3 activation in adipose tissue but not in liver when
compared to HFD or Chow diet (Fig. 6b, c). Finally, obese
and normal mice orally administered T-AG17 showed
liver positive PAS staining (Fig. 6a), reflecting an increase
of cytoplasmic glycogen inclusions.
Discussion
We have shown that orally administered T-AG17 modu-
lates adipocyte differentiation in vitro and induces adi-
pocyte apoptosis in vivo. Oral administration of T-AG17
(0.175 mg/kg daily over 2 weeks) decreased fat cell vol-
ume in WAT.
Incubation with T-AG17 prevents differentiation of
3T3-L1 cells to mature adipocytes, as shown by a
decrease in fat droplet formation by oil red staining
(Fig. 1a, b). Fat droplet formation is one of the final
stages of adipocyte differentiation [43]. This finding is
consistent with the previous observations that T-AG17
suppresses insulin-mediated fatty acid synthesis in rat
white adipocytes [33] and also that Tyrphostin AG490
(which bears the same pharmacophore as T-AG17) in-
hibits adipogenesis by disrupting STAT3 signaling in
human adipocytes through inhibition of JAK2 [44]. This
finding suggests that T-AG17 might be a potential
Fig. 4 T-AG17 administration and body weight in animals exposed to HFD. a Mice were exposed to HFD (60% kcal from fat) or chow diet during
18 weeks. b Body weight was determined every week. Changes in body weight are expressed in gr. c Body weight change after 2 weeks of oral
T-AG17 administration. Graphs show the normalized results of mean ± SEM for n = 9–12 and statistical significance after using unpaired Student’s
t test. *p < 0.05
Fig. 5 T-AG17 promotes apoptotic cell death in adipose tissue. Mice
were exposed to HFD (60% kcal from fat) or Chow diet during
18 weeks and T-AG17(0.175 mg/kg) was orally administered during
2 weeks. Pro caspase 3 activation was evaluated using
immunohistochemistry. PAS staining was performed to evaluate
glycogen synthesis
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effective adipogenesis-blocking agent; therefore, we
tested the tolerance and therapeutic effects in a murine
model of obesity.
In diet-induced obese C57BL/6 mice, T-AG17 does
not induce weight loss, as we had originally hypothe-
sized. Interestingly, the DNP uncoupler does induce
weight loss at thermoneutrality (30 °C) [10], which
differs from our study. However, T-AG17 did promote
an apparent decrease in the size of adipocytes and a
significant activation of caspase 3-dependent apoptosis
(Figs. 5, 6). The decrease in adipocyte size might be me-
diated by MMU-induced lipolysis and down regulation
of lipid synthesis [6]. Tyrphostins, in particular, have
been characterized as classical inductors of apoptosis by
inhibiting protein tyrosine kinase activity [30], suggest-
ing that T-AG17 might be a potential inductor of apop-
totic cell death in adipocytes. Indeed, T-AG17 has been
shown to inhibit cell growth and induce apoptosis in
other cell types [31, 38, 39]. These evidence suggest that
T-AG17 activates the apoptotic pathway in adipocytes,
although no overall weight loss was observed.
Defects in adipocyte tissue expandability and hyper-
trophy lead to ectopic fat accumulation in metabolically
relevant organs, including liver [7]. In a fatty liver, trigly-
ceride (TG) accumulation, either as small or large lipid
deposits, is called micro- or macrovesicular steatosis,
respectively [45–47]. Microvesicular steatosis, gradually
followed by macrovesicular steatosis, is experimentally
induced by 6–10 weeks of HFD feeding [22, 48, 49],
which correlates with an elevation in liver enzymes
(AST and ALT) [45, 50]. Our results agree with these
findings, with mice exhibiting macrovesicular steatosis
after 12 weeks of HFD feeding. To the best of our know-
ledge, the T-AG17- induced switch from macrovesicular
to microvesicular liver steatosis in the HFD group (Fig. 6)
is unprecedented. Also, while T-AG17 increases lipid in-
clusions in hepatocytes as shown by oil red staining
(Fig. 6), we did not find any changes in serum AST
levels, suggesting no histological lesions in liver. We
hypothesize that this is a transient condition whereby
fatty acids are being temporarily exported to the liver
from WAT. In any case, our observations parallel those
of Dianzani and Scuro [51], who reported increases in
hepatic fat droplets in albino rats 48–96 h after injec-
tions with DNP, following by glycogen infiltration after
120 h and decreased in neutral fat droplets. T-AG17 ad-
ministration for 2 weeks results in a microvesicular stea-
tosis phenotype with normal levels of liver enzymes.
Livers from human donors with moderate and severe
macrovesicular steatosis are considered unfit for trans-
plantation [53]. Therefore, our findings support a role of
T-AG17 as a MMU capable of inducing the transition
from macrovesicular to microvesicular steatosis in liver
and potentially improving the metabolic body profile.
Finally, our findings show that obese mice treated with
T-AG17 accumulate glycogen in the liver. Previously, in-
jection of DNP in albino rats has been shown to also
cause hepatic glycogen infiltration [51], and treatment of
obese rats with a controlled-release formulation of DNP
led to an 80% increase in liver glycogen content [18],
which is associated with reversal of hypoglycemia. Our
data are consistent with evidence showing that glycogen
accumulates in the liver of rats following prolonged ad-
ministration of DNP, in contrast to other parenchymal or-
gans [18], and also with the finding that MMU-triggered
by FCCP induces glucose uptake in adipocytes [6].
Conclusions
T-AG17 blocks adipocyte differentiation in vivo and in
vitro, promotes efficient apoptotic cell death of adipocytes
in vivo, and a switch from macrovesicular to microvesicular
steatosis during positive energy balance in a diet-induced
obesity mice model. Thus, our data support the develop-
ment of T-AG17 as a candidate to pharmacologic preven-
tion/treatment of obesity and fatty liver disease.
Fig. 6 T-AG17 shifts macrovesicular to microvesicular steatosis in
liver. a Mice were exposed to HFD or Chow as described and T-
AG17(0.175 mg/kg) was orally administered during two weeks. H/E,
oil red staining, pro caspase 3 activation and PAS staining were
performed in adipose tissue (b) or liver (c) to evaluate morphology,
fat accumulation, apoptosis activation and glycogen synthesis,
respectively. For immunohistochemistry analysis, we used ANOVA
test followed by Kruskal-Wallis test one-way. The data is presented
as mean±SEM unless stated.. *p < 0.05
Camacho et al. Lipids in Health and Disease  (2018) 17:128 Page 9 of 11
Funding
This work was funded by the National Council of Science and Technology in
Mexico (CONACYT) (Grant number: 255317) and the Dirección de
Investigación y Desarrollo, Ayon Industries, Monterrey, México.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
AC and RO contributed to the study design, data interpretation and
manuscript writing; JC, AS, JJ, JG, CA and GC performed experiments and
collected data. All authors read and approved the final manuscript.
Ethics approval
All the experiments were performed using wild-type C57BL/6 male mouse
2 months old. Animals were handled according to the NIH guide for the care
and use of laboratory animals (NIH Publications No. 80–23, revised in 1996),
based on the Basel Declaration to implement the ethical principles of Re-
placement, Reduction and Refinement of experimental animal models and
with approval of the local Animal Care Committee. All efforts were made to
minimize the number of animals used and their suffering.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina,
Universidad Autónoma de Nuevo León (UANL), Monterrey, Mexico. 2Unidad
de Neurometabolismo, Centro de Investigación y Desarrollo en Ciencias de
la Salud (CIDICS), UANL, Monterrey, Mexico. 3Departamento de Histologia,
UANL Facultad de Medicina, Monterrey, Mexico. 4Unidad de Bioimagen,
UANL, CIDICS, Monterrey, Mexico. 5Unidad de Genómica, UANL, CIDICS,
Monterrey, Mexico. 6Unidad de Modelos Experimentales, UANL, CIDICS,
Monterrey, Mexico. 7Unidad de Innovación Biomédica, A.C, Monterrey, Nuevo
León, Mexico. 8Dirección de Innovación Disruptiva, Ayon Industries,
Monterrey, Mexico. 9Dirección de Investigación y Desarrollo, Ayon Industries,
Monterrey, Mexico. 10División de Ciencias de la Salud, Instituto Tecnológico y
de Estudios Superiores de Monterrey (ITESM), Monterrey, NL, Mexico.
11Unidad de Genómica. Unidad de Neurometabolismo, CIDICS, UANL, Dr
Carlos Canseco s/n. Colonia Mitras Centro, CP64460 Monterrey, Nuevo León,
Mexico.
Received: 17 November 2017 Accepted: 18 May 2018
References
1. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al.
Type 2 diabetes mellitus. Nat Rev Dis Prim [Internet]. 2015;1:15019.
2. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy
implications. Nat Rev Endocrinol [Internet]. 2013;9:13–27.
3. Gustafson B, Smith U. Regulation of white adipogenesis and its relation to
ectopic fat accumulation and cardiovascular risk. Atherosclerosis. 2015;24:
27–35.
4. Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis.
Eur J Cell Biol. 2013;92:229–36.
5. Gustafson DB, Smith U. The WNT inhibitor dickkopf 1 and bone
morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in
humans. Diabetes. 2012;61:1217–24.
6. Tejerina S, De Pauw A, Vankoningsloo S, Houbion A, Renard P, De
Longueville F, et al. Mild mitochondrial uncoupling induces 3T3-L1
adipocyte de-differentiation by a PPARgamma-independent mechanism,
whereas TNFalpha-induced de-differentiation is PPARgamma dependent. J
Cell Sci [Internet]. 2009;122:145–55.
7. Moreno-Indias I, Tinahones FJ. Impaired adipose tissue expandability and
lipogenic capacities as ones of the main causes of metabolic disorders. J
Diabetes Res. 2015;2015:970375.
8. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the
metabolic syndrome-an allostatic perspective. Biochim Biophys Acta-Mol
Cell Biol Lipids. 2010;1801:338–49.
9. De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T. Mitochondrial (Dys)
function in adipocyte (De) differentiation and systemic metabolic
alterations. Am J Pathol [Internet]. 2009;175:927–39.
10. Goldgof M, Xiao C, Chanturiya T, Jou W, Gavrilova O, Reitman ML. The
chemical uncoupler 2,4-dinitrophenol (DNP) protects against diet-induced
obesity and improves energy homeostasis in mice at thermoneutrality. J
Biol Chem. 2014;289:19341–50.
11. Schrauwen P, van Marken Lichtenbelt WD. Combatting type 2 diabetes by
turning up the heat. Diabetologia. 2016;59:2269–79.
12. Liu D, Zhang Y, Gharavi R, Park HR, Lee J, Siddiqui S, et al. The mitochondrial
uncoupler DNP triggers brain cell mTOR signaling network reprogramming
and CREB pathway up-regulation. J Neurochem. 2015;134:677–92.
13. Cerqueira FM, Laurindo FRM, Kowaltowski AJ. Mild mitochondrial
uncoupling and calorie restriction increase fasting eNOS, Akt and
mitochondrial biogenesis. PLoS One. 2011;6:e18433.
14. Wu B, Jiang M, Peng Q, Li G, Hou Z, Milne GL, et al. 2,4 DNP improves
motor function, preserves medium spiny neuronal identity, and reduces
oxidative stress in a mouse model of Huntington’s disease. Exp Neurol.
2017;293:83–90.
15. Caldeira Da Silva CC, Cerqueira FM, Barbosa LF, Medeiros MHG, Kowaltowski
AJ. Mild mitochondrial uncoupling in mice affects energy metabolism,
redox balance and longevity. Aging Cell. 2008;7:552–60.
16. Madeiro da Costa RF, Blanco Martinez AM, Ferreira ST. 2,4-Dinitrophenol
blocks neurodegeneration and preserves sciatic nerve function after trauma.
J Neurotrauma [Internet]. 2010;27:829–41.
17. Modrianský M, Gabrielová E. Uncouple my heart: the benefits of inefficiency.
J Bioenerg Biomembr. 2009;41:133–6.
18. Perry RJ, Zhang D, Zhang X-M, Boyer JL, Shulman GI. Controlled-release
mitochondrial protonophore reverses diabetes and steatohepatitis in rats.
Science (80-) [Internet]. 2015;347:1253–6.
19. Wu D, Zheng N, Qi K, Cheng H, Sun Z, Gao B, et al. Exogenous hydrogen
sulfide mitigates the fatty liver in obese mice through improving lipid
metabolism and antioxidant potential. Med Gas Res [Internet]. 2015;5:1.
20. Brand MD. Uncoupling to survive? The role of mitochondrial inefficiency in
ageing. Exp Gerontol. 2000;35:811–20.
21. Tao H, Zhang Y, Zeng X, Shulman GI, Jin S. Niclosamide ethanolamine-
induced mild mitochondrial uncoupling improves diabetic symptoms in
mice. Nat Med [Internet]. 2014;20:1263–9.
22. Liang W, Verschuren L, Mulder P, Van Der Hoorn JWA, Verheij J, Van Dam
AD, et al. Salsalate attenuates diet induced non-alcoholic steatohepatitis in
mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol.
2015;172:5293–305.
23. Romaschenko VP, Zinovkin RA, Galkin II, Zakharova VV, Panteleeva AA,
Tokarchuk AV, et al. Low concentrations of uncouplers of oxidative
phosphorylation prevent inflammatory activation of endothelial cells by
tumor necrosis factor. Biochem [Internet]. 2015;80:610–9.
24. Fu YY, Zhang M, Turner N, Zhang LN, Dong TC, Gu M, et al. A novel
chemical uncoupler ameliorates obesity and related phenotypes in mice
with diet-induced obesity by modulating energy expenditure and food
intake. Diabetologia. 2013;56:2297–307.
25. Brennan JP, Berry RG, Baghai M, Duchen MR, Shattock MJ. FCCP is
cardioprotective at concentrations that cause mitochondrial oxidation
without detectable depolarisation. Cardiovasc Res. 2006;72:322–30.
26. Brennan JP, Southworth R, Medina RA, Davidson SM, Duchen MR, Shattock
MJ. Mitochondrial uncoupling, with low concentration FCCP, induces ROS-
dependent cardioprotection independent of KATP channel activation.
Cardiovasc Res. 2006;72:313–21.
27. Ungvari Z, Orosz Z, Labinskyy N, Rivera A, Xiangmin Z, Smith K, et al.
Increased mitochondrial H2O2 production promotes endothelial NF-kappaB
activation in aged rat arteries. Am J Physiol Heart Circ Physiol [Internet].
2007;293:H37–47.
28. Sagara Y, Ishige K, Tsai C, Maher P. Tyrphostins protect neuronal cells from
oxidative stress. J Biol Chem [Internet]. 2002;277:36204–15.
29. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative
agents and dissectors of signal transduction. FASEB J [Internet]. 1992;6:
3275–82.
30. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu
Rev Biochem. 2006;75:93–109.
Camacho et al. Lipids in Health and Disease  (2018) 17:128 Page 10 of 11
31. Gillespie J, Dye JF, Schachter M, Guillou PJ. Inhibition of pancreatic cancer
cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Br
J Cancer. 1993;68:1122–6.
32. Golomb G, Fishbein I, Banai S, Mishaly D, Moscovitz D, Gertz SD, et al.
Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat
carotid artery injury model. Atherosclerosis [Internet]. 1996;125:171–82.
33. Ohkura K, Hori H. Modification of cell response to insulin by membrane-
acting agents in rat white adipocytes: analysis of structural features by
computational simulation. Bioorganic Med Chem. 2001;9:3023–33.
34. Anand AR, Cucchiarini M, Terwilliger EF, Ganju RK. The tyrosine kinase Pyk2
mediates lipopolysaccharide-induced IL-8 expression in human endothelial
cells. J Immunol [Internet]. 2008;180:5636–44.
35. Park YK, Lee J, Hong VS, Choi JS, Lee TY, Jang BC. Identification of KMU-3, a
novel derivative of gallic acid, as an inhibitor of adipogenesis. PLoS One.
2014;9:e109344.
36. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a
mechanism of production of reactive oxygen species in mitochondria. FEBS
Lett. 1997;416:15–8.
37. Turpaev K, Ermolenko M, Cresteil T, Drapier JC. Benzylidenemalononitrile
compounds as activators of cell resistance to oxidative stress and
modulators of multiple signaling pathways. A structure-activity relationship
study. Biochem Pharmacol. 2011;82:535–47.
38. Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron
N, et al. The tyrphostin AG17 induces apoptosis and inhibition of cdk2
activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res. 1997;
57:2434.
39. Holtick U, Vockerodt M, Pinkert D, Schoof N, Stürzenhofecker B, Kussebi N,
et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a
target of tyrphostin AG17 which confers sensitization for apoptosis.
Leukemia. 2005;19:936–44.
40. Pérez A, Ojeda P, Ojeda L, Salas M, Rivas CI, Vera JC, et al. Hexose
transporter GLUT1 harbors several distinct regulatory binding sites for
flavones and tyrphostins. Biochemistry. 2011;50:8834–45.
41. Diaz B, Fuentes-Mera L, Tovar A, Montiel T, Massieu L, Martínez-Rodríguez
HG, et al. Saturated lipids decrease mitofusin 2 leading to endoplasmic
reticulum stress activation and insulin resistance in hypothalamic cells. Brain
Res. 2015;1627:80–9.
42. Delint-Ramirez I, Maldonado Ruiz R, Torre-Villalvazo I, Fuentes-Mera L, Garza
Ocañas L, Tovar A, et al. Genetic obesity alters recruitment of TANK-binding
kinase 1 and AKT into hypothalamic lipid rafts domains. Neurochem Int.
2015;80:23–32.
43. Qi Y, Sun L, Yang H. Lipid droplet growth and adipocyte development:
mechanistically distinct processes connected by phospholipids. Biochim
Biophys Acta. 2017;1862:1273–83.
44. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, Cooper-DeHoff RM, Wabitsch
M, Clare-Salzler M, et al. The tyrphostin agent AG490 prevents and reverses
type 1 diabetes in NOD mice. PLoS One. 2012;7:e36079.
45. Barrera F, George J. Non-alcoholic fatty liver disease: more than just ectopic
fat accumulation. Drug Discov Today Dis Mech. 2013;10:e47.
46. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ.
Sources of fatty acids stored in liver and secreted via lipoproteins in patients
with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51.
47. Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids.
World J Gastroenterol. 2014;20:1746–55.
48. Ragab SMM, Abd Elghaffar SK, El-Metwally TH, Badr G, Mahmoud MH, Omar
HM. Effect of a high fat, high sucrose diet on the promotion of non-
alcoholic fatty liver disease in male rats: the ameliorative role of three
natural compounds. Lipids Health Dis [Internet]. 2015;14:83.
49. Mulder P, Liang W, Wielinga PY, Verschuren L, Toet K, Havekes LM, et al.
Macrovesicular steatosis is associated with development of lobular
inflammation and fibrosis in diet-induced non-alcoholic steatohepatitis
(NASH). Inflamm Cell Signal. 2015;2:e804.
50. Walther TC, Farese RV. Lipid droplets and cellular lipid metabolism. Annu
Rev Biochem [Internet]. 2012;81:687–714.
51. Evers DJ, Westerkamp AC, Spliethoff JW, Pully VV, Hompes D, Hendriks BHW,
et al. Diffuse reflectance spectroscopy: toward real-time quantification of
steatosis in liver. Transpl Int. 2015;28:465–74.
Camacho et al. Lipids in Health and Disease  (2018) 17:128 Page 11 of 11
